PMID- 35224109
OWN - NLM
STAT- MEDLINE
DCOM- 20220329
LR  - 20220502
IS  - 2314-6753 (Electronic)
IS  - 2314-6745 (Print)
VI  - 2022
DP  - 2022
TI  - Correlation between Acylcarnitine and Peripheral Neuropathy in Type 2 Diabetes 
      Mellitus.
PG  - 8115173
LID - 10.1155/2022/8115173 [doi]
LID - 8115173
AB  - OBJECTIVE: In patients with type 2 diabetes mellitus (T2DM), it is unknown 
      whether acylcarnitine changes in the patient's plasma as diabetic peripheral 
      neuropathy (DPN) occurs. The purpose of the present study was to investigate the 
      correlation between acylcarnitines and DPN in Chinese patients with T2DM. 
      METHODS: A total of 508 patients admitted to the First Affiliated Hospital of 
      Jinzhou Medical University were included in this study, and all of whom were 
      hospitalized for T2DM from January 2018 to December 2020. The diagnostic criteria 
      for DPN were based on the 2017 Chinese Guidelines for the Prevention of Type 2 
      Diabetes. The contents of 25 acylcarnitine metabolites in fasting blood were 
      determined by mass spectrometry. The measured acylcarnitines were classified by 
      factor analysis, and the factors were extracted. To determine the correlation 
      between acylcarnitines and DPN, binary logistic regression analysis was applied. 
      RESULTS: Among the 508 T2DM patients, 270 had DPN. Six factors were extracted 
      from 25 acylcarnitines, and the cumulative contribution rate of variance was 
      61.02%. After the adjustment for other potential confounding factors, such as 
      other carnitines and conventional risk factors, Factor 2 was positively 
      associated with an increased risk of DPN (OR: 1.38, 95% CI: 1.13-1.69). Factor 2 
      contained acetylcarnitine (C2), propionylcarnitine (C3), butylcarnitine (C4), and 
      isovalerylcarnitine (C5). CONCLUSIONS: Plasma levels of short-chain 
      acylcarnitines (C2, C3, C4, and C5) were positively associated with DPN risk.
CI  - Copyright (c) 2022 Zhenni An et al.
FAU - An, Zhenni
AU  - An Z
AD  - Department of Endocrinology, First Affiliated Hospital of Jinzhou Medical 
      University, 121001, China.
FAU - Zheng, Danmeng
AU  - Zheng D
AD  - Department of Endocrinology, First Affiliated Hospital of Jinzhou Medical 
      University, 121001, China.
FAU - Wei, Dongzhuo
AU  - Wei D
AD  - Department of Clinical Discipline of Chinese and Western Integrative Medicine, 
      Liaoning University of Traditional Chinese Medicine, 110847, China.
FAU - Jiang, Dingwen
AU  - Jiang D
AD  - Department of Endocrinology, First Affiliated Hospital of Jinzhou Medical 
      University, 121001, China.
FAU - Xing, Xuejiao
AU  - Xing X
AD  - Department of Endocrinology, First Affiliated Hospital of Jinzhou Medical 
      University, 121001, China.
FAU - Liu, Chang
AU  - Liu C
AUID- ORCID: 0000-0002-6662-1921
AD  - Department of Endocrinology, First Affiliated Hospital of Jinzhou Medical 
      University, 121001, China.
LA  - eng
PT  - Journal Article
DEP - 20220217
PL  - England
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
RN  - 0 (acylcarnitine)
RN  - S7UI8SM58A (Carnitine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Body Mass Index
MH  - Carnitine/*analogs & derivatives/metabolism/pharmacology/therapeutic use
MH  - China
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/complications/drug therapy/physiopathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peripheral Nervous System Diseases/*drug therapy/etiology
MH  - Risk Factors
PMC - PMC8872664
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/03/01 06:00
MHDA- 2022/03/30 06:00
PMCR- 2022/02/17
CRDT- 2022/02/28 05:40
PHST- 2021/10/07 00:00 [received]
PHST- 2022/01/14 00:00 [revised]
PHST- 2022/02/08 00:00 [accepted]
PHST- 2022/02/28 05:40 [entrez]
PHST- 2022/03/01 06:00 [pubmed]
PHST- 2022/03/30 06:00 [medline]
PHST- 2022/02/17 00:00 [pmc-release]
AID - 10.1155/2022/8115173 [doi]
PST - epublish
SO  - J Diabetes Res. 2022 Feb 17;2022:8115173. doi: 10.1155/2022/8115173. eCollection 
      2022.